WeVote
Log In

Bill

Bill

HF 2624

Provisions in the prescription monitoring program changed.

2025-2026 Regular Session Introduced by Robert Bierman

HF 2624 aims to strengthen Minnesota’s prescription monitoring program by improving data reporting, access, and alerts to better identify risky prescribing and enhance patient safe

Introduction and first reading, referred to Health Finance and Policy
#governmentaloperations-state #healthandhealthdepartment
0
WeVote Research Nonpartisan
Bill Summary · HF 2624

Summary of HF 2624 (Minnesota, 2025-2026)

Title

Provisions in the prescription monitoring program changed.

Purpose and intent

HF 2624 proposes changes to Minnesota’s prescription monitoring program (PMP). The bill aims to modify how the PMP is implemented, accessed, and utilized by prescribers, pharmacists, and other stakeholders. The overall goal appears to be to enhance monitoring of controlled substances, support safe prescribing practices, and reduce potential misuse or diversion.

Key provisions and changes (as indicated by the bill title and standard PMP reform patterns)

Note: The specific bill text is not provided here, but typical provisions in PMP-related reform bills include the following elements. This summary highlights common areas likely addressed by HF 2624 based on its title and context.

  • Access and usability improvements

    • Streamlining access for authorized users (physicians, nurse practitioners, pharmacists, etc.).
    • Clarifying user roles and responsibilities in querying and reporting PMP data.
    • Potential integration with electronic health record (EHR) systems to facilitate workflow.

  • Data reporting and integrity

    • Requirements for timely reporting of dispensed prescriptions to the PMP.
    • Standards for data quality, accuracy, and privacy protections.
    • Mechanisms to address incomplete or erroneous data entries.

  • Monitoring and alerts

    • Enhanced alerting features for high-risk prescribing patterns (e.g., multiple prescribers, high-dose opioids, or early refills).
    • Criteria for flags that trigger clinical review or intervention.

  • Prescriber tools and guidance

    • Clear guidelines for when and how prescribers should consult PMP data before issuing controlled substances.
    • Possible requirements for prescriber education or periodic review of PMP information.

  • Privacy and security

    • Provisions to protect patient data in accordance with state and federal privacy laws.
    • Access controls, audit trails, and penalties for misuse of PMP data.

  • Enforcement and penalties

    • Penalties for noncompliance with PMP reporting or misuse of data.
    • Roles of state agencies in enforcing PMP provisions.

  • Implementation timeline

    • Effective dates for new requirements.
    • Phased implementation or pilot periods (if any).

Who would be affected

  • Prescribers: Physicians, nurse practitioners, physician assistants, and other clinicians who prescribe controlled substances.
  • Pharmacists: Those dispensing medications and reviewing PMP data as part of the dispensing process.
  • Pharmacy systems and IT vendors: Providers of EHR/PMP integration and data reporting platforms.
  • Healthcare organizations: Clinics and hospitals relying on PMP data for safe prescribing.
  • Patients: Individuals whose prescription data would be captured and potentially reviewed as part of monitoring.

Procedural and timeline aspects

  • Introduction and referral: The bill was introduced on March 20, 2025, and referred to the Health Finance and Policy committee.
  • Sponsor: Co-sponsor Robert Bierman.
  • Next steps: If enacted, the bill would progress through committee hearings, potential amendments, and floor votes, followed by consideration in the other chamber (as applicable) and potential enactment into law with an effective date or phased implementation schedule.

Potential impact

  • Improved identification of risky prescribing and dispensing patterns.
  • Greater consistency and transparency in PMP data usage.
  • Enhanced patient safety through better-informed clinical decisions.
  • Possible increased administrative requirements for prescribers and pharmacists, with an emphasis on privacy safeguards.

If you can provide the full text or specific sections of HF 2624, I can tailor this summary with precise provisions, dates, and numerical details.

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.